A1.04 Multiplex platform for diagnosis and classification in patients with AML

Multiplex platform for the diagnosis and classification of acute myeloid leukemia (AML). With the development of this new multiplex platform various genetic alterations will be quickly detected in a small blood sample from the patient with AML, which will allow for a rapid, early and personalized decision on the therapy to be initiated.

Date Start

Jan. 2, 2023

Date End

Dec. 31, 2025